ImaginAb inks deal with pharma developer in China

2016 10 18 16 55 18 858 Chinese Flag Button 400

Immuno-PET developer ImaginAb has signed an exclusive license with DongCheng Pharmaceutical Group to commercialize cancer imaging radiotracers across China.

ImaginAb's radiotracer candidate zirconium-89-labeled minibody (Zr-89 Df-Crefmirlimab) aims to bind to human CD8 T-cell receptors for quantitative PET imaging of tumors in cancer patients. Initially, it will be used in third-party clinical trials, with the goal of obtaining market authorization in the country.

Under the terms of the license, ImaginAb will receive a license fee and be entitled to receive potential milestone payments and double-digit royalties on its CD8 immuno-PET product. No other details were disclosed.

Page 1 of 436
Next Page